RIO DE JANEIRO, (Reuters) – Brazil’s Sao Paulo state is expecting to receive on Wednesday ingredients from Sinovac Biotech Ltd that will allow local production of 8.6 million doses of COVID-19 vaccine, the state government said in a statement yesterday.
The ingredients are in Beijing’s airport, in China, awaiting discharge and will be used by Sao Paulo’s state-funded Butantan Institute, which has a partnership with Sinovac to produce the vaccines in Brazil.
